American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · May 2012
Case ReportsFatal agranulocytosis associated with psychotropic medication use.
A patient's death due to severe hematologic adverse effects of the concomitant use of four psychotropic medications is reported. ⋯ A 40-year old woman with a history of acute psychotic symptoms developed agranulocytosis and neutropenia after starting therapy that included lamotrigine, mirtazapine, quetiapine, and venlafaxine.
-
Sweet's syndrome (also known as acute febrile neutrophilic dermatosis) in two patients receiving azacitidine therapy is reported. ⋯ Azacitidine was the apparent cause of Sweet's syndrome in a patient with MDS and another with CMML. Both responded well to corticosteroid therapy. After resolution of the reaction, decitabine was given to the first patient and azacitidine to the second, without complications.
-
Am J Health Syst Pharm · May 2012
Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
The results of a hospital's initiative to evaluate and improve compliance with federally mandated risk evaluation and mitigation strategies (REMS) are presented. ⋯ Quality-improvement initiatives including staff education, incorporation of REMS requirements into existing policy, development of an electronic resource, and creation of a separate storage section for drugs subject to REMS were implemented at a large academic medical center to help ensure compliance with inpatient-applicable REMS requirements.
-
Am J Health Syst Pharm · May 2012
ReviewEribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of eribulin in patients with metastatic breast cancer are reviewed. ⋯ Eribulin, a novel synthetic antimicrotubule agent that binds to the vinca domain of tubulin and inhibits the polymerization of tubulin, offers a new treatment option for metastatic breast cancer or locally advanced breast cancer.